Thursday, October 06, 2022 9:41:16 AM
Regen BioPharma, Inc. Files Provisional Patent on CAR-T Cell Capable of Attracting and Educating Naïve T Cells to Kill Cancer
Novel Approach Expected to Expand Using of CAR-T Therapy to Solid Tumors
SAN DIEGO, Oct. 5, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today filing of a provisional patent application with the USPTO entitled "Enhancement of T Cell Homing to Tumors Through Augmentation of Chemokine Responsiveness and Activation Dependent Chemokine Secretion" with the United States Patent and Trademark Office .
The patent application discloses novel means of generating CAR-T cells which upon activation stimulate production of various T cell-specific compounds, called "chemokines" which act as molecular beacons that call in all surrounding T cells and instruct them to kill the cancer cell.
According to an industry report, "Overall, the global CAR-T cell market for all indications was worth $1.7 billion in 2021 and is forecast to reach $2.4 billion by the end of 2022. By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. This makes CAR-T cells one of the fastest growing and potentially profitable therapeutic areas in oncology[1]."
"Despite the significant market size of CAR-T cells, this approach has only shown benefit in so called "liquid tumors", which as leukemias and lymphomas. Overall, for reasons known and unknown, solid tumors such as breast, lung, colon, skin and kidney cancer have not benefited" Said David Koos, President, CEO and Chairman. "Our scientific advisors and collaborators tell us that one of the shortcomings of current treatments is that they rely exclusively on the engineered CAR-T cells, which usually are inactivated by the tumor. In the current patent filed we overcome this by using the initial CAR-T cells to stimulate a chain reaction that culminates in education of the patient's immune response to kill the tumor."
The Company previously has obtained issued US patent #11,090,332 (which covers means of generating T cell immune responses to the solid tumor antigen survivin) as well as US Patent # 11,141,471 covering NR2F6 silenced CAR-T. By combining these technologies with the ones disclosed in the abovementioned patent application filing the Company anticipates development of novel and potentially effective CAR-T cells capable of killing solid tumors, which would significantly expand the market of this new therapy.
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM